Top 10 Challenges in Cancer Immunotherapy

Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Anagnostou, 2017, Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer, Cancer Discov., 7, 264, 10.1158/2159-8290.CD-16-0828 Antonia, 2017, Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N. Engl. J. Med., 377, 1919, 10.1056/NEJMoa1709937 Aptsiauri, 2018, The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses, Curr. Opin. Immunol., 51, 123, 10.1016/j.coi.2018.03.006 Argiles, 2017, Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC), Ann. Oncol., 28, 10.1093/annonc/mdx302.003 Atkins, 2018, Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC), Journal of Clinial Onocology, 36 Ayers, 2017, IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade, J. Clin. Invest., 127, 2930, 10.1172/JCI91190 Ayers, 2019, Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy, Clin. Cancer Res., 25, 1564, 10.1158/1078-0432.CCR-18-1316 Azizi, 2018, Single-Cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment, Cell, 174, 1293, 10.1016/j.cell.2018.05.060 Bacac, 2016, A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors, Clin. Cancer Res, 22, 3286, 10.1158/1078-0432.CCR-15-1696 Balar, 2017, Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial, Lancet, 389, 67, 10.1016/S0140-6736(16)32455-2 Bargou, 2008, Tumor regression in cancer patients by very low doses of a T cell-engaging antibody, Science, 321, 974, 10.1126/science.1158545 Barker, 2009, I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy, Clin. Pharmacol. Ther., 86, 97, 10.1038/clpt.2009.68 Barlesi, 2018, Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study, Lancet Oncol., 19, 1468, 10.1016/S1470-2045(18)30673-9 Botticelli, 2019, A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab, J. Transl. Med., 17, 99, 10.1186/s12967-019-1847-x Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68, 394, 10.3322/caac.21492 Carbone, 2017, First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer, N. Engl. J. Med., 376, 2415, 10.1056/NEJMoa1613493 Carvajal-Hausdorf, 2019, Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC), J. Immunother. Cancer, 7, 65, 10.1186/s40425-019-0540-1 Cary, 2018, Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution, Clin. Genitourin. Cancer, 16, e307, 10.1016/j.clgc.2017.10.008 Castle, 2014, Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma, BMC Genomics, 15, 10.1186/1471-2164-15-190 Chau, 2018, 1239TiP MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types, Ann. Oncol., 29, 10.1093/annonc/mdy288.110 Chawla, 2018, Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers, J. Med. Econ., 21, 543, 10.1080/13696998.2017.1423488 Chen, 2013, Statistical issues and challenges in immuno-oncology, J. Immunother. Cancer, 1 Chen, 2017 Chen, 2018, Combinations of Bevacizumab With Cancer Immunotherapy, Cancer J., 24, 193, 10.1097/PPO.0000000000000327 Chen, 2013, Oncology meets immunology: the cancer-immunity cycle, Immunity, 39, 1, 10.1016/j.immuni.2013.07.012 Chen, 2017, Elements of cancer immunity and the cancer-immune set point, Nature, 541, 321, 10.1038/nature21349 Cherkasova, 2013, Endogenous retroviruses as targets for antitumor immunity in renal cell cancer and other tumors, Front. Oncol., 3, 243, 10.3389/fonc.2013.00243 Chong, 2017, PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR, Blood, 129, 1039, 10.1182/blood-2016-09-738245 Claret, 2018, A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics, Clin. Cancer Res, 24, 3292, 10.1158/1078-0432.CCR-17-3662 Crispe, 2014, Immune tolerance in liver disease, Hepatology, 60, 2109, 10.1002/hep.27254 Cristescu, 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362, eaar3593, 10.1126/science.aar3593 Czuczman, 2004, Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up, J. Clin. Oncol., 22, 4711, 10.1200/JCO.2004.04.020 Dirix, 2018, Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study, Breast Cancer Res. Treat., 167, 671, 10.1007/s10549-017-4537-5 Dong, 2017, PD-1 and its ligands are important immune checkpoints in cancer, Oncotarget, 8, 2171, 10.18632/oncotarget.13895 Dranoff, 2011, Experimental mouse tumour models: what can be learnt about human cancer immunology?, Nat. Rev. Immunol., 12, 61, 10.1038/nri3129 Ebert, 2016, MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade, Immunity, 44, 609, 10.1016/j.immuni.2016.01.024 Ebrahimi-Nik, 2019, Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection, JCI Insight, 5 Efremova, 2018, Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution, Nat. Commun, 9, 32, 10.1038/s41467-017-02424-0 Eng, 2019, Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial, Lancet Oncol., 20, 849, 10.1016/S1470-2045(19)30027-0 Eroglu, 2018, High response rate to PD-1 blockade in desmoplastic melanomas, Nature, 553, 347, 10.1038/nature25187 Faroudi, 2003, Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: manifestation of a dual activation threshold, Proc. Natl. Acad. Sci. USA, 100, 14145, 10.1073/pnas.2334336100 Flippot, 2016, Oncogenic viruses: Lessons learned using next-generation sequencing technologies, Eur. J. Cancer, 61, 61, 10.1016/j.ejca.2016.03.086 Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J. Exp. Med., 192, 1027, 10.1084/jem.192.7.1027 Freeman-Keller, 2016, Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes, Clin. Cancer Res., 22, 886, 10.1158/1078-0432.CCR-15-1136 Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat. Rev. Cancer, 12, 298, 10.1038/nrc3245 Galon, 2019, Approaches to treat immune hot, altered and cold tumours with combination immunotherapies, Nat. Rev. Drug Discov., 18, 197, 10.1038/s41573-018-0007-y Gandara, 2018, Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab, Nat. Med., 24, 1441, 10.1038/s41591-018-0134-3 Gandhi, 2018, Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer, N. Engl. J. Med., 378, 2078, 10.1056/NEJMoa1801005 Garrido, 1993, Natural history of HLA expression during tumour development, Immunol. Today, 14, 491, 10.1016/0167-5699(93)90264-L Gauci, 2019, Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation, Clin. Cancer Res., 25, 946, 10.1158/1078-0432.CCR-18-0793 Gentilini, 2018, The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium, Int. J. Mol. Sci., 19, 2885, 10.3390/ijms19102885 George, 2015, Comprehensive genomic profiles of small cell lung cancer, Nature, 524, 47, 10.1038/nature14664 Gökbuget, 2018, Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia, Blood, 131, 1522, 10.1182/blood-2017-08-798322 Gould, 2015, Translational value of mouse models in oncology drug development, Nat. Med., 21, 431, 10.1038/nm.3853 Graeber, 2019 Grasso, 2018, Genetic Mechanisms of Immune Evasion in Colorectal Cancer, Cancer Discov., 8, 730, 10.1158/2159-8290.CD-17-1327 Griss, 2019, B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma, Nat. Commun., 10, 4186, 10.1038/s41467-019-12160-2 Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N. Engl. J. Med., 368, 1509, 10.1056/NEJMoa1215134 Guo, 2018, Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing, Nat. Med., 24, 978, 10.1038/s41591-018-0045-3 Haanen, 2017, Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 28, iv119, 10.1093/annonc/mdx225 Hamid, 2018, 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.9516 Hamid, 2019, Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab, Clin. Cancer Res., 25, 6061, 10.1158/1078-0432.CCR-18-3488 Hansen, 2018, Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study, Ann. Oncol., 29, 1807, 10.1093/annonc/mdy232 Hegde, 2016, The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition, Clin. Cancer Res., 22, 1865, 10.1158/1078-0432.CCR-15-1507 Hegde, 2018, Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics, Semin. Cancer Biol., 52, 117, 10.1016/j.semcancer.2017.12.002 Hellmann, 2018, Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden, N. Engl. J. Med., 378, 2093, 10.1056/NEJMoa1801946 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Herbst, 2016, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, 387, 1540, 10.1016/S0140-6736(15)01281-7 Herbst, 2019, Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and –042 trials, Ann. Oncol., 30, v851, 10.1093/annonc/mdz394.077 Hirsch, 2017, PD-L1 Immunohistochemistry assays for lung cancer: results from Phase 1 of the Blueprint PD-L1 IHC assay comparison project, J. Thorac. Oncol., 12, 208, 10.1016/j.jtho.2016.11.2228 Hochster, 2017, Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC), J. Clin. Oncol., 35, 673, 10.1200/JCO.2017.35.4_suppl.673 Hodi, 2016, Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab, J. Clin. Oncol., 34, 1510, 10.1200/JCO.2015.64.0391 Hodi, 2018, Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy, J. Clin. Oncol., 36, 850, 10.1200/JCO.2017.75.1644 Hodi, 2018, Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial, Lancet Oncol., 19, 1480, 10.1016/S1470-2045(18)30700-9 Hoffmann, 2005, Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct, Int. J. Cancer, 115, 98, 10.1002/ijc.20908 Homet Moreno, 2016, Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells, Cancer Immunol. Res., 4, 845, 10.1158/2326-6066.CIR-16-0060 Huang, 1996, The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product, Proc. Natl. Acad. Sci. USA, 93, 9730, 10.1073/pnas.93.18.9730 Hugo, 2016, Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma, Cell, 165, 35, 10.1016/j.cell.2016.02.065 Iglesia, 2016, Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types, J. Natl. Cancer Inst., 108, 10.1093/jnci/djw144 Ikeda, 2019, A Phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. EMSO 2019 Congress, Cancer Res., 79, v253, 10.1158/1538-7445.AM2019-CT061 Jamal-Hanjani, 2017, Tracking the Evolution of Non-Small-Cell Lung Cancer, N. Engl. J. Med., 376, 2109, 10.1056/NEJMoa1616288 Joshi, 2019, Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer, Nat. Med., 25, 1549, 10.1038/s41591-019-0592-2 Jotte, 2018, IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC, J. Clin. Ontol., 36 June, 2018, CAR T cell immunotherapy for human cancer, Science, 359, 1361, 10.1126/science.aar6711 Kantarjian, 2017, Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia, N. Engl. J. Med., 376, 836, 10.1056/NEJMoa1609783 Kersten, 2017, Genetically engineered mouse models in oncology research and cancer medicine, EMBO Mol. Med., 9, 137, 10.15252/emmm.201606857 Kim, 2016, Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure), Ann. Oncol., 8, 1492, 10.1093/annonc/mdw217 Kobold, 2018, Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy, Front. Oncol., 8, 285, 10.3389/fonc.2018.00285 Köhnke, 2015, Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab, J. Hematol. Oncol., 8, 111, 10.1186/s13045-015-0213-6 Kowanetz, 2018, Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1), Proc. Natl. Acad. Sci. USA, 115, E10119, 10.1073/pnas.1802166115 Landi, 2019, Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer, J. Immunother. Cancer, 7, 316, 10.1186/s40425-019-0793-8 Lavin, 2017, Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses, Cell, 169, 750, 10.1016/j.cell.2017.04.014 Le, 2015, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Leach, 1996, Enhancement of antitumor immunity by CTLA-4 blockade, Science, 271, 1734, 10.1126/science.271.5256.1734 Lechner, 2013, Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy, J. Immunother., 36, 477, 10.1097/01.cji.0000436722.46675.4a Lee, 2019, Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, hepatocellular carcinoma (HCC). ESMO 2019 Congress, Ann. Oncol., 30, v851 Lemery, 2017, First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication, N. Engl. J. Med., 377, 1409, 10.1056/NEJMp1709968 Li, 2019, CD3 bispecific antibody-induced cytokine release is dispensable for cytotoxic T cell activity, Sci. Transl. Med., 11, eaax8861, 10.1126/scitranslmed.aax8861 Lin, 2017, Estimation of treatment effects in weighted log-rank tests, Contemp. Clin. Trials Commun., 8, 147, 10.1016/j.conctc.2017.09.004 Linnemann, 2014, TCR repertoires of intratumoral T-cell subsets, Immunol. Rev., 257, 72, 10.1111/imr.12140 Liu, 2018, Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer, Eur. J. Cancer, 101, 114, 10.1016/j.ejca.2018.06.033 Long, 2019, Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study, Lancet Oncol., 20, 1083, 10.1016/S1470-2045(19)30274-8 Lukas, 2018, Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma, J. Neurooncol., 140, 317, 10.1007/s11060-018-2955-9 Marabelle, 2019, Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. ESMO 2019 Congress, Ann. Oncol., 30, v475, 10.1093/annonc/mdz253.018 Mariathasan, 2018, TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Martin, 2012, First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation, Biol. Blood Marrow Transplant., 18, 1150, 10.1016/j.bbmt.2012.04.005 Massard, 2016, Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer, J. Clin. Oncol., 34, 3119, 10.1200/JCO.2016.67.9761 May, 2014, Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy, AIDS, 28, 1193, 10.1097/QAD.0000000000000243 McDermott, 2018, Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma, Nat. Med., 24, 749, 10.1038/s41591-018-0053-3 McGranahan, 2015, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution, Cancer Cell, 27, 15, 10.1016/j.ccell.2014.12.001 McGranahan, 2016, Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, 351, 1463, 10.1126/science.aaf1490 McGranahan, 2017, Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution, Cell, 171, 1259, 10.1016/j.cell.2017.10.001 Mellman, 2016, De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute, Cancer Immunol. Res., 4, 279, 10.1158/2326-6066.CIR-16-0045 Mosely, 2017, Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery, Cancer Immunol. Res., 5, 29, 10.1158/2326-6066.CIR-16-0114 Motzer, 2018, LBA6_PRJAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC), Ann. Oncol., 29, 10.1093/annonc/mdy424.036 Motzer, 2018, Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma, N. Engl. J. Med., 378, 1277, 10.1056/NEJMoa1712126 Nass, 2018, Accelerating anticancer drug development - opportunities and trade-offs, Nat. Rev. Clin. Oncol., 15, 777, 10.1038/s41571-018-0102-3 Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 Oliver, 2018, Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses, Front. Immunol., 9, 70, 10.3389/fimmu.2018.00070 Olnes, 2016, Effects of Systemically Administered Hydrocortisone on the Human Immunome, Sci. Rep., 6, 23002, 10.1038/srep23002 Oyama, 1998, Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells, J. Immunol., 160, 1224, 10.4049/jimmunol.160.3.1224 Panda, 2018, Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma, JCI Insight, 3, 121522, 10.1172/jci.insight.121522 Pao, 2018, Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer, Cancer Discov., 8, 395, 10.1158/2159-8290.CD-17-1320 Parsons, 2018, Multiclonal tumor origin: Evidence and implications, Mutat. Res., 777, 1, 10.1016/j.mrrev.2018.05.001 Paz-Ares, 2018, Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer, N. Engl. J. Med., 379, 2040, 10.1056/NEJMoa1810865 Perea, 2017, The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration, Int. J. Cancer, 140, 888, 10.1002/ijc.30489 Pereira, 2017, Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition, Clin. Cancer Res, 23, 3203, 10.1158/1078-0432.CCR-16-1946-T Peters, 2019, Cancer Res., 79, 10.1158/1538-7445.AM2019-1267 Peters, 2019, Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 Part 1 final analysis, Ann. Oncol., 30, v851, 10.1093/annonc/mdz394.075 Pillai, 2016, Liver metastases and sensitivity to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC), J. Clin. Oncol., 34, 10.1200/JCO.2016.34.15_suppl.e20665 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849 Pradel, 2016, Macrophage Susceptibility to Emactuzumab (RG7155) Treatment, Mol. Cancer Ther., 15, 3077, 10.1158/1535-7163.MCT-16-0157 Pui, 2015, Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration, J. Clin. Oncol., 33, 2938, 10.1200/JCO.2014.59.1636 Purbhoo, 2004, T cell killing does not require the formation of a stable mature immunological synapse, Nat. Immunol., 5, 524, 10.1038/ni1058 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Reck, 2019, Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial, Lancet Respir. Med., 7, 387, 10.1016/S2213-2600(19)30084-0 Redman, 2018, Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer, J. Immunother. Cancer, 6, 91, 10.1186/s40425-018-0409-8 Restifo, 1996, Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy, J. Natl. Cancer Inst., 88, 100, 10.1093/jnci/88.2.100 Riley, 2019, Delivery technologies for cancer immunotherapy, Nat. Rev. Drug Discov., 18, 175, 10.1038/s41573-018-0006-z Rini, 2017, Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC), J. Clin. Ontol., 35 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 Rizvi, 2018, LBA6 Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC. ESMO Immuno-Oncology Congress 2018Ann, Oncol., 29, x39 Robbins, 2015, A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response, Clin. Cancer Res., 21, 1019, 10.1158/1078-0432.CCR-14-2708 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Rosenthal, 2019, Neoantigen-directed immune escape in lung cancer evolution, Nature, 567, 479, 10.1038/s41586-019-1032-7 Sade-Feldman, 2018, Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma, Cell, 175, 998, 10.1016/j.cell.2018.10.038 Salmon, 2012, Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors, J. Clin. Invest., 122, 899, 10.1172/JCI45817 Salmon, 2019, Host tissue determinants of tumour immunity, Nat. Rev. Cancer, 19, 215 Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet., 51, 202, 10.1038/s41588-018-0312-8 Scheper, 2019, Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers, Nat. Med., 25, 89, 10.1038/s41591-018-0266-5 Schuster, 2018, Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel, Blood, 132 Seymour, 2017, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol., 18, e143, 10.1016/S1470-2045(17)30074-8 Shields, 2018, Immune Modulation Therapy and Imaging: Workshop Report, J. Nucl. Med., 59, 410, 10.2967/jnumed.117.195610 Shin, 2017, Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations, Cancer Discov., 7, 188, 10.1158/2159-8290.CD-16-1223 Shrimali, 2017, Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis, Cancer Immunol. Res., 5, 755, 10.1158/2326-6066.CIR-17-0292 Simon, 2017, Critical Review of Umbrella, Basket, and Platform Designs for Oncology Clinical Trials, Clin. Pharmacol. Ther., 102, 934, 10.1002/cpt.814 Simoni, 2018, Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates, Nature, 557, 575, 10.1038/s41586-018-0130-2 Simonsen, 2018, The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies, Eur. J. Cancer, 103, 259, 10.1016/j.ejca.2018.07.127 Smith, 2018, Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma, J. Clin. Invest., 128, 4804, 10.1172/JCI121476 Sosa, 2018, Clinical assessment of immune-related adverse events, Ther. Adv. Med. Oncol., 10, 10.1177/1758835918764628 Spigel, 2018, FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC, J. Thorac. Oncol., 13, 1733, 10.1016/j.jtho.2018.05.004 Spigel, 2019, IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. EMSO 2019 Congress. Ann, Oncol., 30, v851 Spranger, 2015, Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404 Spranger, 2014, Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment, J. Immunother. Cancer, 2 Sugiura, 2018, Metabolic Barriers to T Cell Function in Tumors, J. Immunol., 200, 400, 10.4049/jimmunol.1701041 Takahashi, 2008, Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells, J. Clin. Invest., 118, 1099, 10.1172/JCI34409C1 Tang, 2018, Comprehensive analysis of the clinical immuno-oncology landscape, Ann. Oncol., 29, 84, 10.1093/annonc/mdx755 Tao, 2018, Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology, Annu. Rev. Med., 69, 319, 10.1146/annurev-med-062016-050343 Thorsson, 2018, The Immune Landscape of Cancer, Immunity, 48, 812, 10.1016/j.immuni.2018.03.023 Tiegs, 2010, Immune tolerance: what is unique about the liver, J. Autoimmun., 34, 1, 10.1016/j.jaut.2009.08.008 Topp, 2015, Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study, Lancet Oncol., 16, 57, 10.1016/S1470-2045(14)71170-2 Tran, 2016, T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer, N. Engl. J. Med., 375, 2255, 10.1056/NEJMoa1609279 Tsao, 2018, PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project, J. Thorac Oncol., 13, 1302, 10.1016/j.jtho.2018.05.013 Tsimberidou, 2018, Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement, J. Immunother. Cancer, 6, 108, 10.1186/s40425-018-0426-7 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Tumeh, 2017, Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC, Cancer Immunol. Res., 5, 417, 10.1158/2326-6066.CIR-16-0325 Varadarajan, 2011, A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis, J. Clin. Invest., 121, 4322, 10.1172/JCI58653 von Pawel, 2017, 1314PAssociation between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK, Ann. Oncol., 28, mdx380.017, 10.1093/annonc/mdx380.017 Wang, 2011, The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation, Immunity, 35, 871, 10.1016/j.immuni.2011.09.021 Wang, 2017, Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma, Cancer Immunol. Res., 5, 357, 10.1158/2326-6066.CIR-16-0287 Wang, 2018, Toxicities Associated With PD-1/PD-L1 Blockade, Cancer J., 24, 36, 10.1097/PPO.0000000000000296 Weber, 2017, Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma, J. Clin. Oncol., 35, 785, 10.1200/JCO.2015.66.1389 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin. Cancer Res., 15, 7412, 10.1158/1078-0432.CCR-09-1624 Xiang, 2019, The Contribution of the Immune System in Bone Metastasis Pathogenesis, Int. J. Mol. Sci., 20, 999, 10.3390/ijms20040999 Zaretsky, 2016, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma, N. Engl. J. Med., 375, 819, 10.1056/NEJMoa1604958 Zheng, 2017, Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing, Cell, 169, 1342, 10.1016/j.cell.2017.05.035 Zhou, 2008, Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine, Clin. Trials, 5, 181, 10.1177/1740774508091815 Zhou, 2019, Liver-Resident NK Cells Control Antiviral Activity of Hepatic T Cells via the PD-1-PD-L1 Axis, Immunity, 50, 403, 10.1016/j.immuni.2018.12.024 Zhukovsky, 2016, Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection, Curr. Opin. Immunol., 40, 24, 10.1016/j.coi.2016.02.006 Zitvogel, 2016, Mouse models in oncoimmunology, Nat. Rev. Cancer, 16, 759, 10.1038/nrc.2016.91 Zloza, 2017, Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer, J. Immunother. Cancer, 5, 77, 10.1186/s40425-017-0278-6